Immune Checkpoint Pathway Expression in Lymphocyte Subpopulations in Patients with Common Variable Immunodeficiency and Chronic Lymphocytic Leukemia

SIMPLE SUMMARY: Our research explores the realm of immune cells to better understand patients with chronic lymphocytic leukemia (CLL) and common variable immunodeficiency (CVID). By examining immune checkpoints such as PD-1/PD-L1, CTLA-4/CD86, and CD200R/CD200 in different blood lymphocyte subpopulations, we aim to extract valuable insights that may improve not only our understanding of these diseases but also contribute to improving treatment conditions and the occurrence of subsequent complications and the development of hematological cancers. We hope that the knowledge about the role of these signaling pathways in the development and progression of these two diseases will allow us to develop modern and personalized diagnostic and therapeutic strategies, which in the future may allow monitoring the immune system of patients with CVID and CLL. ABSTRACT: This study aims to gain a deeper understanding of chronic lymphocytic leukemia (CLL) and common variable immunodeficiency (CVID) by studying immune cells and specific immune checkpoint signaling pathways. The analysis of the percentage of selected immune points and their ligands (PD-1/PD-L1, CTLA-4/CD86, and CD200R/CD200) on peripheral blood lymphocyte subpopulations was performed using flow cytometry, and additional analyses determining the serum concentration of the above-mentioned molecules were performed using enzyme immunoassay tests. The obtained results indicate several significant changes in the percentage of almost all tested molecules on selected subpopulations of T and B lymphocytes in both CVID and CLL patients in relation to healthy volunteers and between the disease subunits themselves. The results obtained were also supported by the analysis of the serum concentration of soluble molecules tested. By uncovering valuable insights, we hope to enhance our comprehension and management of these conditions, considering both immunodeficiencies and hematological malignancies. Understanding the role of these signaling pathways in disease development and progression may lead to the development of modern, personalized diagnostic and therapeutic strategies. Ultimately, this knowledge may enable the monitoring of the immune system in patients with CVID and CLL, paving the way for improved patient care in the future.